JAK/TYK2

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell Arteritis https://t.co/WP8JGpHc6p https://t.co/x9m870mCJ4

Links:

Dr. John Cush @RheumNow( View Tweet )
Livedoid vasculopathy (LV) is a rare chronic microvascular thrombosis dz w/ hypercoagulability and inflammation. Lit Search found 15 articles, 41 LV pts Rx w/ biologics & JAK inhib. 88% w/ positive responses & pain relief. TNFi were most used, then JAK inhibitors… https://t.co/3ugGdUlYcI https://t.co/0aXRKRi5RA
Dr. John Cush @RheumNow( View Tweet )
PSO.Palmoplantar.jpg

Deucravacitinib in Psoriasis - 5 Year Outcomes

Jack Cush, MD

BMS released new five-year results from the POETYK PSO long-term extension (LTE) trial of deucravacitinib in treating patients with moderate-to-severe plaque psoriasis. The data was presented by Dr. Marc Lebwohl at the Winter Clinical Dermatology Conference in Hawaii

Read Article
cost.price_.drugs_.pills_.jpg

The Cartel is Coming for Rheumatology

Eric Dein, MD

"What Do Blockbuster Drugs & The Black Market All Have in Common?" asked Dr. Madelaine Feldman at RheumNow Live 2025. They thrive, she explained, on market exclusivity "... until they don't." At first glance, the pharmaceutical marketplace may not appear like a crime drug ring, but Dr.

Read Article
RheumNow Podcast square

Valentine RNL 2025 Review (2.14.2025)

Jack Cush, MD

Dr. Jack Cush reviews highlights from RheumNow Live 2025 held in Dallas, TX on Feb. 8-9, 2025.

Read Article
#RNL2025 @RheumNow JAKi in DM: @JuliePaikMD- 10 DM pts open label on JAKi. 7/10 improved from mod/severe to mild. In 96wk extension, 6 of 7 continued response 145 case reports for tofa, bari, ruxolitinib. Role in helping calcinosis? Pruritu? Brepocitinib (JAK1/TYK2i) study

Eric Dein @ericdeinmd( View Tweet )

Pearls on Dermatomyositis: -Negative myomarker does not r/o DM -Pruritus can be a skin manifestation in DM🚨 -Combination therapy upfront =achieve faster remission -Evidence for JAK inhibitors in management -JAKis seem to have good effect in DM-calcinosis -In DM with rapidly… https://t.co/J3iiDa6ph7 https://t.co/0WTHKa97bt

Links:

Adela Castro @AdelaCastro222( View Tweet )
Hepatitis B (Keep)

AGA Guideline: Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals

Jack Cush, MD

The American Gastroenterology Association has published its revised clinical practice guidelines for the prevention and treatment of hepatitis B virus (HBV) reactivation in at-risk patients, particularly those with immune-mediated disease, receiving immunomodulatory therapy and steroids.

Read Article
North American Real-world EHR data of PsA & axSpA pts (n 2200 Ea.) found no higher rates of CVD (acute MI, CVA or revascularization) or solid cancers (breast, colorectal, lung, prostate) when comparing JAKi to either TNFi or IL-17i use (over 3 years). https://t.co/macjpWxdnY https://t.co/9gXiomU3YD

Links:

Dr. John Cush @RheumNow( View Tweet )
DMARDs,biologics,RA

Getting to Remission - Without Biologics

Jack Cush, MD

Analysis of data from two early rheumatoid arthritis (ERA) cohorts shows remission in RA is primarily seen in those who do not require biologic DMARDs (bDMARDs), while those needing bDMARDs are less apt to achieve remission.

Read Article
BACHELOR Trial - Baricitinib in Early Polymyalgia Rheumatica Lancet reports a French study demonstrating the efficacy of baricitinib in patients with polymyalgia rheumatica (PMR). Glucocorticoids are the mainstay of therapy in PMR patients and may be problematic in older… https://t.co/svLmE6OBWm https://t.co/K8sdROswxV
Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

Fallen Angels (1.17.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com; and pays homage to colleagues who passed away in 2024.

Read Article
PMR,flag

BACHELOR Trial - Baricitinib in Early Polymyalgia Rheumatica

Jack Cush, MD

Lancet reports a French study demonstrating the efficacy of baricitinib in patients with polymyalgia rheumatica (PMR).

Read Article
RheumNow Podcast square

Alive in 2025 (1.10.2025)

Jack Cush, MD

Dr. Jack Cush brings in the new year with a review of the latest from RheumNow.com

Read Article
RheumNow Live 2025 kicks off in just 6 weeks! Join us Feb 8-9 in Dallas for an unmatched rheumatology event. https://t.co/VH2ahP1XUy Don’t miss expert insights on JAK Inhibitors from: 🔹 Madelaine Feldman, MD 🔹 Joseph F. Merola, MD 🔹 Christina Charles-Schoeman, MD… https://t.co/9dRVwLNufF https://t.co/r88g6QMBC3

Links:

Dr. John Cush @RheumNow( View Tweet )
shingles_0.jpg

Anti-Zoster Drug Prevents Shingles in Lupus Patients on Anifrolumab

MedPage Today

The antiviral drug valaciclovir (Valtrex), given prophylactically, kept patients with systemic lupus erythematosus (SLE) under treatment with anifrolumab (Saphnelo) from having herpes zoster attacks, researchers said, offering a potential alternative to zoster vaccination.

Read Article
psA.fil_.toes_.jpg

Phase 3 Trial Results of Deucravacitinib in Psoriatic Arthritis

Jack Cush, MD

Bristol Myers Squibb announced recently the results from POETYK PsA-1 and POETYK PsA-2, Phase 3 trials pivotal trials of deucravacitinib (DEUC) in adults with active psoriatic arthritis. Both trials met their primary endpoint, demonstrating ACR20 efficacy after 16 weeks of treatment with DEUC

Read Article
JAK inhibitors are effective at repigmentation in vitiligo. 5 RCTs, 1,550 pts showed >50% improvement (TVASI50; RR 2.67) or >75% (FVASI75; RR 3.97_ JAKi increased skin AE, but not significantly different from placebo pts. https://t.co/zIreYlUyLt https://t.co/pCWKL2vSVs

Links:

Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

ICYMI: VITAL Info on Autoimmune Disease (2.9.2024)

Jack Cush, MD

Dr. Jack Cush reviews the journal reports from the past week on RheumNow.com. Highlights are summarized by three songs: "Stairway to Heaven", "You're No Good", and "How Long (has this been going on)".

Read Article
RheumNow Live 2025 kicks off in just 6 weeks! Join us Feb 8-9 in Dallas for an unmatched rheumatology event. https://t.co/vkoA3UHZGg Don’t miss expert insights on JAK Inhibitors from: 🔹 Madelaine Feldman, MD 🔹 Joseph F. Merola, MD 🔹 Christina Charles-Schoeman, MD… https://t.co/jIzOzPIcML https://t.co/EB2clBvq0g

Links:

Dr. John Cush @RheumNow( View Tweet )
A cohort of 9 patients with Anti-MDA5 DM with RPILD who was treated with combination of RTX, JAKi, and GCS had significantly bettery survival compared to historical cohort in this abstract! #ACR24 @RheumNow https://t.co/PMVn5Pb1b3

Links:

Dr. John Cush @RheumNow( View Tweet )

Upadacitinib in GCA. Merkel et al. SELECT-GCA study. Sustained remission week 52 Upa (+26 week steroid) 46% vs PBO (+52 week steroid) 29%. Reduced flare rates with UPA (see picture). Similar to GiACTA results. @RheumNow #ACR24 Abstr#0770 https://t.co/f7OwxAggaf… https://t.co/PUuwo0MLso https://t.co/JBzokT9icx

Links:

Dr. John Cush @RheumNow( View Tweet )
ICYMI: JAKi in inflammatory myositis? #ACR24 will showcase nearly 3000 abstracts. With the expanding use of JAK inhibitors, there will be some interesting presentations for off label use. There have been some uncontrolled data that tofacitinib reduced inflammatory myositis… https://t.co/8XOYOsDsD4 https://t.co/MF0EGO0BJz
Dr. John Cush @RheumNow( View Tweet )
Seo RNL

Best of 2024: Vasculitis Pearls

Richard Conway, MBBChBAO, PhD

Once again RheumNow Live 2024 really delivered with high impact learning packed into short sessions. As someone with an interest in vasculitis it was fantastic to see four of my favorite speakers in the Vasculitis Mavens and STEP talks. They gave us what we really want from these talks –

Read Article
question-mark-1872634_640.jpg

ICYMI: JAKi in inflammatory myositis?

Janet Pope, MD, MPH, FRCPC

Abstract 1731 is a small RCT of baricitinib in inflammatory myositis comparing early start baricitinib to later start.

Read Article

Recent Blogs

JAKi for PMR: Safe, or a Concern for Older Adults?

David Liew, FRACP
Dr. David Liew
JAK inhibitors obviously have dominated a lot of the discussion in our therapeutic landscape over the last couple of years. What about their use in polymyalgia rheumatica? Let's consider. Read Post

Infections Rheums Should Worry About

Cassandra Calabrese, DO
TB.EMimage.CDC_.jpg
With the increasing development and use of new biologics and oral targeted therapies to treat RA and other immune mediated inflammatory diseases, an awareness of infection risk and prevention has become of increasing interest as well. While our patients may be susceptible to many different types of infections depending on immunosuppressive regimen, age and co-morbidities, I’ll highlight a few of the “usual suspects”. Read Post
×